<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01250795</url>
  </required_header>
  <id_info>
    <org_study_id>FhCMB HAI-05-001</org_study_id>
    <nct_id>NCT01250795</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity Of A Recombinant H5N1 Vaccine In Adults</brief_title>
  <official_title>A Phase 1a/b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Investigate the Safety, Reactogenicity, and Immunogenicity of FhCMB HAI-05, a Recombinant Hemagglutinin (rHA) Vaccine Derived From Influenza A/Indonesia/05/2005 (H5N1), in Healthy Adults 18 to 49 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fraunhofer, Center for Molecular Biotechnology</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fraunhofer, Center for Molecular Biotechnology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, immunogenicity,and tolerability of a H5N1&#xD;
      Vaccine in healthy adults.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety</measure>
    <time_frame>200 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>immunogenicity</measure>
    <time_frame>day 43</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>15 ug HAI-05 plus Alhydrogel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>45 ug HAI-05 plus Alhydrogel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>90 ug HAI-05 plus Alhydrogel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>90 ug HAI-05 in saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HAI-05 Influenza Vaccine</intervention_name>
    <description>injection, vaccine, twice every 3 weeks</description>
    <arm_group_label>15 ug HAI-05 plus Alhydrogel</arm_group_label>
    <arm_group_label>45 ug HAI-05 plus Alhydrogel</arm_group_label>
    <arm_group_label>90 ug HAI-05 in saline</arm_group_label>
    <arm_group_label>90 ug HAI-05 plus Alhydrogel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects accepted for this study must meet the following inclusion criteria:&#xD;
&#xD;
          -  Male or female aged 18 to 49 years inclusive&#xD;
&#xD;
          -  Able to give written informed consent to participate&#xD;
&#xD;
          -  Healthy as determined by medical history, physical examination, vital signs, and&#xD;
             clinical safety laboratory examinations at baseline&#xD;
&#xD;
          -  Females should fulfill one of the following criteria:&#xD;
&#xD;
               1. At least 1 year post-menopausal&#xD;
&#xD;
               2. Surgically sterile&#xD;
&#xD;
               3. Will use oral, implantable, transdermal, or injectable contraceptives for 30 days&#xD;
                  prior to first vaccination and until 28 days after each vaccination&#xD;
&#xD;
               4. Willing to abstain from sexual intercourse or use another reliable form of&#xD;
                  contraception approved by the investigator (e.g., intrauterine device [IUD],&#xD;
                  female condom, diaphragm with spermicide, cervical cap, use of condom by the&#xD;
                  sexual partner, or a sterile sexual partner) for study duration and until 28 days&#xD;
                  after vaccination&#xD;
&#xD;
          -  Women of childbearing potential must have a negative urine pregnancy test within 24&#xD;
             hours preceding receipt of each dose&#xD;
&#xD;
          -  Comprehension of the study requirements, expressed availability for the required study&#xD;
             period, and ability to attend scheduled visits and to be contacted by telephone&#xD;
             throughout the follow-up period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Any of the following are cause for exclusion from the study:&#xD;
&#xD;
          -  Prior receipt of any influenza vaccine containing H5&#xD;
&#xD;
          -  Presence of significant uncontrolled medical or psychiatric illness (acute or&#xD;
             chronic); includes institution of new medical or surgical treatment or a significant&#xD;
             dose alteration for uncontrolled symptoms or drug toxicity within 3 months of&#xD;
             screening and reconfirmed on Day 1 prior to vaccination&#xD;
&#xD;
          -  Positive serology for human immunodeficiency virus (HIV 1 or HIV 2), hepatitis B&#xD;
             surface antigen (HBsAg). or hepatitis C (HCV)&#xD;
&#xD;
          -  Cancer or treatment for cancer within 3 years excluding basal cell carcinoma or&#xD;
             squamous cell carcinoma which are allowed&#xD;
&#xD;
          -  Presence of any medical condition that may be associated with impaired immune&#xD;
             responsiveness, including diabetes mellitus&#xD;
&#xD;
          -  Presently receiving (or has a history of receiving) during the preceding 3 month&#xD;
             period any medications or other treatments that may adversely affect the immune&#xD;
             system, such as allergy injections, immune globulin, interferon, immunomodulators,&#xD;
             cytotoxic drugs; other drugs known to be frequently associated with significant major&#xD;
             organ toxicity; or systemic (oral or injectable) corticosteroids (inhaled and topical&#xD;
             corticosteroids allowed)&#xD;
&#xD;
          -  Receipt or planned administration of a nonstudy vaccine within 30 days prior to&#xD;
             vaccination and during the study (Immunization on an emergency basis with Tetanus&#xD;
             Toxoids Adsorbed for adult use vaccine-tetanus and diphtheria [Td] or tetanus,&#xD;
             diphtheria, and pertussis [Tdap] up to 8 days before or at least 8 days after a dose&#xD;
             of study vaccine will be allowed, and administration of study vaccine injection can be&#xD;
             delayed if a nonstudy vaccine has been administered and will be given as soon as&#xD;
             acceptable [as described above] provided the vaccine is not administered within 2&#xD;
             weeks prior to study enrollment.)&#xD;
&#xD;
          -  History of significant allergic reactions (anaphylactic-type reactions, respiratory&#xD;
             difficulties, or angioedema) to injected vaccines or to any of the study vaccine&#xD;
             components&#xD;
&#xD;
          -  History of drug or chemical abuse in the year before the study; positive urine drug&#xD;
             screen at screening.&#xD;
&#xD;
          -  Receipt of any investigational product or nonregistered drug within the 30 days prior&#xD;
             to vaccination or currently enrolled in any investigational drug study or intends to&#xD;
             enroll in such a study within the ensuing study period&#xD;
&#xD;
          -  Receipt of blood or blood products 8 weeks prior to vaccination or planned&#xD;
             administration during the study period&#xD;
&#xD;
          -  Donation of blood or blood products within 8 weeks prior to vaccination or at any time&#xD;
             during the study&#xD;
&#xD;
          -  Acute disease within 72 hours prior to vaccination defined as the presence of a&#xD;
             moderate or severe illness (as determined by the investigator through medical history&#xD;
             and physical examination) with or without fever, or a fever &gt;38ÂºC orally (Study&#xD;
             vaccine can be administered to persons with a minor illness, such as diarrhea, or mild&#xD;
             upper respiratory tract infection with or without low-grade fever, and vaccination can&#xD;
             be delayed until the subject has recovered.)&#xD;
&#xD;
          -  Any condition that, in the opinion of the investigator, might interfere with the&#xD;
             primary study objectives or the subject's safety&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Heartland Research Associates, LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Pharmaceutical Research</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>November 29, 2010</study_first_submitted>
  <study_first_submitted_qc>November 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2010</study_first_posted>
  <last_update_submitted>May 10, 2016</last_update_submitted>
  <last_update_submitted_qc>May 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza in Birds</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

